CRM vs VEEV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CRM is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRM and VEEV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRM and VEEV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Salesforce is the leading provider of cloud-based customer relationship management (CRM) software, helping companies manage sales, customer service, marketing, e-commerce, and analytics. Its core products include Sales Cloud, Service Cloud, Marketing Cloud, and Commerce Cloud, plus a broad platform for building custom applications. Through major acquisitions it also owns Slack (workplace collaboration), Tableau (data visualization and analytics), and MuleSoft (data integration), and it has pushed aggressively into artificial intelligence with its Einstein features and, more recently, Agentforce, a platform for deploying AI agents that automate sales, service, and other workflows. Salesforce makes money primarily through recurring subscription and support revenue, billed per user, giving it highly predictable, sticky software revenue at large scale. It is one of the largest enterprise software companies in the world, headquartered in San Francisco, and serves businesses of all sizes across virtually every industry globally.

Full CRM guide

Veeva Systems Inc. is the dominant provider of cloud software built specifically for the life-sciences industry, serving pharmaceutical, biotech, and medical-device companies. Its products span two broad areas: commercial applications, including its CRM used by drug-company sales and medical teams, and its Vault platform, a content and data-management system used across clinical trials, regulatory submissions, quality, and safety. Because Veeva's software is purpose-built for the highly regulated life-sciences world and is deeply embedded in customers' core workflows, it enjoys strong retention and pricing power, and it earns recurring subscription revenue.

Full VEEV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CRM drivers: Agentforce and AI monetization; Dominant CRM franchise and data moat.
• VEEV drivers: Life-sciences market dominance; Vault CRM transition.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Salesforce's subscription growth has decelerated from its hyper-growth past into the low-to-mid teens or lower, and the durability of reacceleration from AI is unproven. For VEEV, the dominant risk is valuation: as a high-quality software company, Veeva trades at a premium multiple that assumes durable growth, so any slowdown in revenue or the Vault CRM migration could pressure the stock.

Pick CRM if you believe its drivers more; VEEV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CRM and VEEV guides.

CRM. Salesforce trades at a software premium that reflects its CRM market leadership, sticky recurring revenue, and dramatically improved margins and free cash flow. The valuation now balances a maturing growth profile against optionality from AI (Agentforce and Data Cloud). The market is essentially weighing whether AI can reaccelerate growth enough to justify the multiple as core seat growth slows.

VEEV. Figures are approximate and tied to the asOf date; verify live numbers before acting. Unlike many unprofitable software names, Veeva has real earnings, so investors look at both its P/E and growth-adjusted metrics, plus revenue growth, operating margins, and free cash flow. The stock carries a premium valuation that embeds expectations of steady mid-teens growth, a successful Vault CRM transition, and expanding AI adoption. That premium means the shares can fall on any growth disappointment even though the underlying business is high quality.

Headline figures (approximate, early 2026): CRM shows revenue (ttm) ~$38 billion, operating margin (gaap) ~20%; adjusted margins meaningfully higher, revenue growth high-single-digit to low-teens, decelerated from past, dividend yield ~0.5-0.7% (recently initiated); VEEV shows fy2026 revenue Roughly $3.2 billion, up about 16% year over year, q4 fy2026 revenue Around $836 million, up about 16% and ahead of estimates, profitability Highly profitable with strong operating margins and robust free cash flow, vault crm traction More than 150 customers live, dozens of migrations completed, high win rate.

CRM and VEEV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRM and VEEV exposure against your real portfolio. It is not an investment adviser.